TY - JOUR
T1 - Endocrine therapy in post-menopausal women with metastatic breast cancer
T2 - From literature and guidelines to clinical practice
AU - Sini, Valentina
AU - Cinieri, Saverio
AU - De Laurentiis, Michelino
AU - Leo, Angelo D.
AU - Tondini, C.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Current international guidelines recommend endocrine therapy as the initial treatment of choice in hormone receptor positive advanced breast cancer. Endocrine therapy has been a mainstay of hormone responsive breast cancer treatment for more than a century. To date it is based on different approaches,such as blocking the estrogen receptor through selective receptor estrogen modulators, depleting extragonadal peripheral estrogen synthesis by aromatase inhibitors or inducing estrogen receptor degradation using selective down-regulators.Despite estrogen and/or progesterone receptor positive status, up to a quarter of patients could be either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Different mechanisms, either intrinsic or acquired, could be implicated in endocrine resistance.In the present work available endocrine therapies and their appropriate sequences have been reviewed, and the most promising strategies to overcome endocrine resistance have been highlighted.
AB - Current international guidelines recommend endocrine therapy as the initial treatment of choice in hormone receptor positive advanced breast cancer. Endocrine therapy has been a mainstay of hormone responsive breast cancer treatment for more than a century. To date it is based on different approaches,such as blocking the estrogen receptor through selective receptor estrogen modulators, depleting extragonadal peripheral estrogen synthesis by aromatase inhibitors or inducing estrogen receptor degradation using selective down-regulators.Despite estrogen and/or progesterone receptor positive status, up to a quarter of patients could be either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Different mechanisms, either intrinsic or acquired, could be implicated in endocrine resistance.In the present work available endocrine therapies and their appropriate sequences have been reviewed, and the most promising strategies to overcome endocrine resistance have been highlighted.
KW - Advanced breastcancer
KW - Endocrine resistance
KW - Endocrine therapy
KW - Hormone receptor positive
KW - Maintenance
KW - Postmenopausal
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84960399646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960399646&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2016.02.008
DO - 10.1016/j.critrevonc.2016.02.008
M3 - Article
VL - 100
SP - 57
EP - 68
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -